Novel molecule and diagnosis method
CA 2331455 A1 · Owner: Isis Innovation Limited · Inventors: Mcmichael, Andrew James; Bowness, Paul; Allen, Rachel Louise
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A substantially isolated dimer comprising first and second cross-linked polypeptides, wherein said polypeptides comprise the extracellular domain portions of the HLA-B27 heavy chain and are capable of binding a HLA-B27 epitope, or a substantially isolated functional dimeric or multimeric analogue thereof which is capable of binding said HLA-B27 epitope and/or competes for binding to a specific receptor for said dimer. The dimer can be used to determine the onset of, or predisposition to a spondyloarthropathy. The dimer can also be used as a treatment or prophylactic for a spondyloarthropathy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 11, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 11, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 11, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.